Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer By Ogkologos - November 18, 2024 846 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR Worse Survival Observed Among Patients Diagnosed with Cancer During the First... February 16, 2026 EMA Recommends Granting a Marketing Authorisation for Capivasertib April 29, 2024 EMA Recommends Extension of Indications for Selpercatinib April 15, 2026 Adding Sintilimab to Chemoradiotherapy Improves Event-Free Survival in Patients with High-Risk... June 24, 2024 Load more HOT NEWS Survey results reveal attitudes towards cancer screening during the pandemic New on NCI’s Websites for March 2021 Cure Probability Models for Evaluation of Patients with a Previous Cancer... 10 Things I Wish I Knew When I Was First Diagnosed...
